LHRI Signs Gludef™ FDG Supply Agreement with Lantheus Medical Imaging

Feb 16, 2011 - Lawson Health Research Institute Signs Gludef™ FDG Supply Agreement with Lantheus Medical Imaging and Receives Health Canada Establishment License

LONDON, Ontario – Lawson Health Research Institute announced today that it has signed a Manufacturing & Supply Agreement with Lantheus MI Canada, Inc., a subsidiary of Lantheus Medical Imaging, Inc., to produce Gludef™ at Lawson’s Nordal Cyclotron & PET Radiochemistry Facility in London, Ontario.  Under this agreement, Lawson will be able to service fourteen southwest Ontario counties with Gludef, Lantheus Medical Imaging’s version of fludeoxyglucose F-18 injection (also known as FDG), including Brant, Norfolk, Wellington, Waterloo, Grey, Bruce, Huron, Perth, Oxford, Middlesex, Elgin, Lambton, Chatham-Kent, and Essex.

Gludef is a radiopharmaceutical agent indicated for imaging in patients undergoing oncologic diagnostic procedures for the evaluation of single pulmonary nodules (lung cancer diagnosis).  It is used in conjunction with Positron Emission Tomography (PET) scanners.  More......